SFD Stock Analysis: Smithfield Foods, Common | NASDAQ
Packaged Foods | NASDAQ, USA | Market Cap: 8.865m USD | 12M Return: -9.5% | US8322482071 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 34.7M
Qual. Beats: 0
Rev. Trend: 62.4%
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Smithfield Foods, Inc. (NASDAQ: SFD) is a U.S.-headquartered producer of packaged meats and fresh pork products, operating across four segments: Packaged Meats, Fresh Pork, Hog Production, and Other. The Packaged Meats segment sells branded products (Smithfield, Eckrich, Nathans Famous, Farmland, Armour, John Morrell, and others) plus private-label items to retail and foodservice customers. The Fresh Pork segment processes live hogs into primal, sub-primal, and offal cuts for domestic and export markets, including China, Mexico, Japan, South Korea, and Canada.
The Hog Production segment raises hogs on company-owned and contract farms and sells livestock feed, while the Other segment includes a bioscience operation that manufactures heparin (an active pharmaceutical ingredient derived from hog byproducts used to mitigate blood clots) and fresh pork production in Mexico. Founded in 1936 and based in Smithfield, Virginia, Smithfield is a subsidiary of SFDS UK Holdings Limited and re-listed on NASDAQ in January 2025.
As a vertically integrated player in the Packaged Foods & Meats sub-industry (Consumer Staples), Smithfield controls multiple stages of the pork value chain-from hog farming and feed production to slaughter, processing, and branded packaged meats-giving it supply-chain visibility uncommon among peers that focus on processing alone. Its mix of consumer-facing brands and commodity pork exposure ties results to both grocery retail demand and global pork export cycles.
- China export demand swings Fresh Pork segment revenue
- Hog feed costs pressure Pork segment margins
- Packaged meats pricing battles private label competition
| Net Income: 1.06b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.01 > 1.0 |
| NWC/Revenue: 19.72% < 20% (prev 19.89%; Δ -0.17% < -1%) |
| CFO/TA 0.10 > 3% & CFO 1.16b > Net Income 1.06b |
| Net Debt (1.43b) to EBITDA (1.69b): 0.85 < 3 |
| Current Ratio: 2.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (395.8m) vs 12m ago 0.51% < -2% |
| Gross Margin: 13.38% > 18% (prev 13.58%; Δ -0.20% > 0.5%) |
| Asset Turnover: 133.4% > 50% (prev 132.7%; Δ 0.70% > 0%) |
| Interest Coverage Ratio: 38.60 > 6 (EBIT TTM 1.35b / Interest Expense TTM 35.0m) |
| A: 0.25 (Total Current Assets 5.01b - Total Current Liabilities 1.95b) / Total Assets 12.0b |
| B: 0.33 (Retained Earnings 4.01b / Total Assets 12.0b) |
| C: 0.12 (EBIT TTM 1.35b / Avg Total Assets 11.6b) |
| D: 1.49 (Book Value of Equity 7.00b / Total Liabilities 4.70b) |
| Altman-Z'' = 5.10 = AAA |
| DSRI: 1.25 (Receivables 1.01b/773.0m, Revenue 15.5b/14.8b) |
| GMI: 1.02 (GM 13.58% / 13.38%) |
| AQI: 0.95 (AQ_t 0.28 / AQ_t-1 0.30) |
| SGI: 1.04 (Revenue 15.5b / 14.8b) |
| TATA: -0.01 (NI 1.06b - CFO 1.16b) / TA 12.0b) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of August 28, 2026, the stock is trading at USD 22.11 with a total of 1,267,380 shares traded. Over the past week, the price has changed by -0.76%, over one month by -15.66%, over three months by -16.04% and over the past year by -9.53%.
Current recommended Stop Loss: 21.40 (which is 3.2% or 1.3 ATR below the current price).
Smithfield Foods, Common has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SFD.
- StrongBuy: 4
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 30.3 | 36.8% |
P/E Trailing = 8.4067
P/E Forward = 10.2354
P/S = 0.5734
P/B = 1.2661
Revenue TTM = 15.5b USD
EBIT TTM = 1.35b USD
EBITDA TTM = 1.69b USD
Long Term Debt = 2.00b USD (from longTermDebt, last fiscal year)
Short Term Debt = 675.0m USD (from shortTermDebt, last quarter)
Debt = 2.78b USD (from shortLongTermDebtTotal, last quarter) + Leases 386.0m
Net Debt = 1.43b USD (calculated: Debt 2.78b - CCE 1.35b)
Enterprise Value = 10.3b USD (8.87b + Debt 2.78b - CCE 1.35b)
Interest Coverage Ratio = 38.60 (Ebit TTM 1.35b / Interest Expense TTM 35.0m)
EV/FCF = 12.84x (Enterprise Value 10.3b / FCF TTM 802.0m)
FCF Yield = 7.79% (FCF TTM 802.0m / Enterprise Value 10.3b)
FCF Margin = 5.18% (FCF TTM 802.0m / Revenue TTM 15.5b)
Net Margin = 6.84% (Net Income TTM 1.06b / Revenue TTM 15.5b)
Gross Margin = 13.38% ((Revenue TTM 15.5b - Cost of Revenue TTM 13.4b) / Revenue TTM)
Gross Margin QoQ = 12.92% (prev 13.45%)
Tobins Q-Ratio = 0.86 (Enterprise Value 10.3b / Total Assets 12.0b)
Interest Expense / Debt = 1.26% (Interest Expense 35.0m / Debt 2.78b)
Taxrate = 21.02% (285.0m / 1.36b)
NOPAT = 1.07b (EBIT 1.35b * (1 - 21.02%))
Current Ratio = 2.56 (Total Current Assets 5.01b / Total Current Liabilities 1.95b)
Debt / Equity = 0.40 (Debt 2.78b / totalStockholderEquity, last quarter 7.00b)
Debt / EBITDA = 0.85 (Net Debt 1.43b / EBITDA 1.69b)
Debt / FCF = 1.79 (Net Debt 1.43b / FCF TTM 802.0m)
Total Stockholder Equity = 6.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.12% (Net Income 1.06b / Total Assets 12.0b)
RoE = 15.60% (Net Income TTM 1.06b / Total Stockholder Equity 6.78b)
RoCE = 15.38% (EBIT 1.35b / Capital Employed (Equity 6.78b + L.T.Debt 2.00b))
RoIC = 10.71% (NOPAT 1.07b / Invested Capital 9.96b)
WACC = 4.45% (E(8.87b)/V(11.6b) * Re(5.53%) + D(2.78b)/V(11.6b) * Rd(1.26%) * (1-Tc(0.21)))
Discount Rate = 5.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.00 | Cagr: 0.30%
[DCF] Terminal Value 76.34% ; FCFF base≈780.4m ; Y1≈830.5m ; Y5≈988.1m
[DCF] Fair Price = 34.96 (EV 15.2b - Net Debt 1.43b = Equity 13.8b / Shares 393.5m; r=8.35% [WACC [floored]]; 5y FCF grow 7.22% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.46 | # QB: 0
Revenue Correlation: 62.36 | Revenue CAGR: 3.00% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.64 | Chg30d=-1.38% | Revisions=+17% | Analysts=4
EPS current Year (2026-12-31): EPS=2.47 | Chg30d=-6.74% | Revisions=-50% | GrowthEPS=-3.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=2.45 | Chg30d=-4.03% | Revisions=-57% | GrowthEPS=-0.8% | GrowthRev=+0.7%
[Analyst] Revisions Ratio: -46% (up=2, down=8)